Claims for Patent: 6,951,844

Summary for Patent: 6,951,844

Title:	Phenyl naphthol ligands for thyroid hormone receptor
Abstract:	New thyroid receptor ligands are provided which have the general formula I ##STR1## wherein R.sub.1 is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.1-6 alkyl, or substituted or unsubstituted C.sub.3-7 cycloalkyl; R.sub.2 and R.sub.3 are each independently hydrogen, halogen, substituted or unsubstituted C.sub.1-4 alkyl, or substituted or unsubstituted C.sub.3-6 cycloalkyl, wherein at least one of R.sub.2 and R.sub.3 is other than hydrogen; R.sub.4 is a carboxylic acid selected from the group consisting of (CH.sub.2).sub.n COOH, (CH).sub.2 COOH, NHCO(CH.sub.2).sub.n COOH, CONH(CH.sub.2).sub.n COOH and NH(CH.sub.2).sub.m COOH; n is an integer from 0 to 4; and m is an integer from 1 to 4. In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T.sub.3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
Inventor(s):	Hangeland; Jon J. (Morrisville, PA)
Assignee:	Bristol Myers Squibb Company (Princeton, NJ)
Application Number:	10/946,162
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,951,844
Patent Claims:	1. A pharmaceutical composition comprising a compound of the formula I ##STR34## wherein R.sub.3 is selected from the group consisting of halogen, trifluoromethyl, aryl, C.sub.1-6 alkyl and C.sub.3-7 cycloalkyl, wherein the aryl group may optionally be substituted with one or more substituent selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, amino, nitro, cyano, aryl, cycloalkyl, heteroaryl, carboxyl or an alkyl ester thereof, and carboxamide; the C.sub.1-6 alkyl group may optionally be substituted with one or more substituent selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, hydroxy, cyano, nitro, amino, halogen, carboxyl or an alkyl ester thereof, and carboxamide; the C.sub.3-7 cycloalkyl group may optionally be substituted with one or more substituent selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, amino, nitro, cyano, aryl, cycloalkyl, heteroaryl, carboxyl or an alkyl ester thereof, and carboxamide; R.sub.2 and R.sub.3 are each independently selected from the group consisting of hydrogen, halogen, C.sub.1-4 alkyl and C.sub.3-6 cycloalkyl, wherein at least one of R.sub.2 and R.sub.3 is other than hydrogen, and wherein the C.sub.1-6 alkyl group may optionally be substituted with one or more substituent selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, hydroxy, cyano, nitro, amino, halogen, carboxyl or an alkyl ester thereof, and carboxamide; the C.sub.3-7 cycloalkyl group may optionally be substituted with one or more substituent selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, hydroxy, amino, nitro, cyano, aryl, cycloalkyl, heteroaryl, carboxyl or an alkyl ester thereof, and carboxaide; R.sub.4 is selected from the group consisting of (CH.sub.2).sub.n COOH, (CH).sub.2 COOH, NHCO(CH.sub.2).sub.n COOH, CONH(CH.sub.2).sub.n COOH and NH(CH.sub.2).sub.m COOH, or esters thereof; n is an integer from 0 to 4; and m is an integer from 1 to 4, including all stereolsomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof, and at least one additional therapeutic agent selected from the group consisting of other compounds of formula I, metformin, phenformin, glimepiride, glyburide, glicazide, chlorpropamide, glipizide, troglitazone, darglitazone, englitazone, rosiglitazone, pioglitazone, insulin, acarbose, miglitol, GLP-1, alendronate, risedronate, raloxifene, calcitonin, orlistat, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, mazindol, diethylstilbestrol, theophylline, enkephalins, sulbenox, GHRP-6, GHRP-2, GHRP-1, IGF-1, IGF-2, clonidine, sumatriptan, physostigmine, pyndostigmine, parathyroid hormone, estrogen, testosterone, tamoxifen, levonorgestrel, medroxyprogesterone acetate, prednisone, dexamethasone, aspirin, indomethacin, ibuprofen, piroxicam, mycophenolate, infliximab, budesonide, clofazimine, priliximab, diazepam, lorazepam, buspirone, oxazepam, hydroxyzine pamoate, citalopram, fluoxetine, nefazodone, sertraline, tretinoin, diltiazem, verapamil, nifedipine, amlodipine, mybefradil, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride, spironolactone, captopril, zofenapril, pentopril, quinapril, ramipril, lisinopril, losartan, irbesartan, valsartan, sitaxsentan, atrasentan, omaprilat, gemopatrilat, digitalis, ouabain, 9-[4-[4-[[2-(2,2,2-trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-( 2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide, mevastatin, lovastatin, pravastatin, fluvastatin, atorvastatin, cholestyramine, colestipol, imanixil, tetrahydrolipostatin, istmastanylphosphorylcholine, melinamide, nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic, thyrotropin, polythyroid and dronedarone. 2. The pharmaceutical composition of claim 1 wherein said antidiabetic agent is selected from the group consisting of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, troglitazone, pioglitazone, englitazone, darglitazone, rosiglitazone, and insulin.

Details for Patent 6,951,844

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2021-12-07
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2021-12-07